• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » etrials Reports $6.1M Loss

etrials Reports $6.1M Loss

November 12, 2008
CenterWatch Staff

Morrisville, N.C.-based eClinical company etrials reported another quarter of loss, with net losses for the third quarter at $6.1 million, compared with $1.3 million for the same period last year and $2.2 million in net losses for the second quarter of 2008.

Net service revenues were $3.7 million for the third quarter of 2008, down from the same period last year ($4.1 million) and the second quarter of 2008 ($4 million).

“etrials’ third quarter performance was somewhat mixed. We made significant progress in reining in expenses, reducing our operating expenses to a $4.9 million run rate,” said etrials’ interim CEO Chuck Piccirillo in company statement. “However, end of quarter backlog was lighter than we would have liked.”

In an investor conference call yesterday, Piccirillo expressed optimism for the fourth quarter of 2008 based on the timing of 17 studies that began or will begin by the end of the year. Piccirillo said etrials has enlisted a financial advisor to help the board explore strategic growth opportunities, including acquiring other companies.

This comment spurred several call-in questions about why, with etrials’ current financial situation, the eClinical company would consider buying other companies rather than selling itself. etrials executives said they will continue to explore “all aspects of opportunity.”

Upcoming Events

  • 15Apr

    Five Telltale Signs You’re Ready for an Electronic TMF System

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Clinical-Trial-Brainstorming

    FDA, Industry Tackle Problem of Including Older Adults in Trials

  • ClinicalTrialNetwork-360x240.png

    National Community-Based Research Network Would Improve Reach of Trials

  • Bottleneck-360x240.png

    Sites Face Trials Bottleneck After Pandemic, But Also Opportunities

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Genetic Research and IBC Oversight Requirements

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing